Table 2 PSA response and outcome after ADT with or without selective estrogen receptor modulators (n = 15)
ADT (n = 5) | TOPADT (n = 5) | RAPADT (n = 5) | ||
|---|---|---|---|---|
Follow-up period (median, range) | 1169 (431―1631) | 1653 (730―1983) | 1570 (750―1883) | |
PSA nadir (ng/mL) | ≥1 | 1 | 0 | 1 |
0.01–1.0 | 2 | 3 | 3 | |
≤0.01 | 2 | 2 | 1 | |
Biochemical recurrence | No | 2 | 5 | 3 |
Yes | 3 | 0 | 2 | |
Outcome | Alive with disease | 4 | 4 | 5 |
Died of PC | 1 | 0 | 0 | |
Died of other disease | 0 | 1: Died of gastric cancer | 0 | |
Adverse event | Hot flush: 2 | Hot flush: 3, Headache: 1 | Hot flush: 3 | |